Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIRCULATE-PLUS: Myocardial uptake of CardioCell in non-ischaemic heart failure
2021-002246-32Phase 2Completed
- Sponsor
- Krakowski Szpital Specjalistyczny im. Jana Pawła II
- Start
- Jan 2022
- Modality
- Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ischemia-tolerant mesenchymal stem cells in dilated cardiomyopathy (DCM) and Non-Ischaemic Cardiomyopathy (NICM), sponsored by Krakowski Szpital Specjalistyczny im. Jana Pawła II. Primary endpoint: CardioCell delivery success. Started Jan 2022; status: completed.
02
Drugs
ischemia-tolerant mesenchymal stem cells
03
Conditions
dilated cardiomyopathy (DCM)Non-Ischaemic Cardiomyopathy (NICM)
Beyond the preview
Go deeper on 2021-002246-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002246-32.